Scancell Holdings plc (LON:SCLP – Get Free Report) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 14.42 and traded as low as GBX 10. Scancell shares last traded at GBX 10.10, with a volume of 7,500,558 shares traded.
Scancell Stock Up 0.6%
The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The firm has a market capitalization of £108.54 million, a price-to-earnings ratio of -18.48 and a beta of 0.69. The stock has a fifty day moving average of GBX 10.75 and a 200-day moving average of GBX 14.39.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
